BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
G-protein-coupled receptor binding
,
Pseudomonas infection
,
Breast
,
Prozac
,
TGFB1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
AKT3
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Fetal brain
Cerebellar vermis
Saphenous vein
Cerebellum
Thalamus lateral nuclei
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Hydrocephalus
Polydactyly
Allergy to substance
Disease due to Arenavirus
Antiphospholipid syndrome
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Mitogens
quelamycin
Cefoperazone
TGX 221
Fenretinide
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
IGH
GALNT3
FEN1
CENPA
VDR
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Akt3 links mitochondrial function to the regulation of Aurora B and mitotic fidelity.
5,7-Dihydroxy-4-Methylcoumarin enhances osteogenesis and ameliorates osteoporosis via the AKT1 pathw…
Activity-induced synaptic structural modifications by Akt.
A multi-layered network model identifies Akt1 as a common modulator of neurodegeneration.
Identification of XAF1 as an endogenous AKT inhibitor.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ